Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$40.06 - $51.86 $0 - $0
0 New
0 $0
Q2 2024

Aug 14, 2024

BUY
$36.45 - $47.7 $0 - $0
0 New
0 $0
Q1 2024

May 13, 2024

BUY
$42.03 - $53.55 $0 - $0
0 New
0 $0
Q4 2023

Feb 09, 2024

BUY
$43.39 - $51.63 $0 - $0
0 New
0 $0
Q3 2023

Nov 03, 2023

BUY
$38.5 - $47.13 $0 - $0
0 New
0 $0
Q2 2023

Aug 14, 2023

BUY
$34.73 - $43.33 $0 - $0
0 New
0 $0
Q4 2021

Feb 01, 2022

SELL
$25.61 - $35.1 $0 - $0
0 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$33.54 - $40.55 $248,766 - $300,759
-7,417 Closed
0 $0
Q2 2021

Aug 06, 2021

SELL
$34.54 - $47.25 $548,598 - $750,471
-15,883 Reduced 68.17%
7,417 $296,000
Q1 2021

May 14, 2021

BUY
$42.51 - $63.78 $21,255 - $31,890
500 Added 2.19%
23,300 $1.05 Million
Q4 2020

Feb 12, 2021

BUY
$45.3 - $60.27 $9,060 - $12,054
200 Added 0.88%
22,800 $1.29 Million
Q1 2020

May 14, 2020

BUY
$41.6 - $63.4 $108,160 - $164,840
2,600 Added 13.0%
22,600 $1.07 Million
Q2 2019

Aug 13, 2019

BUY
$62.09 - $86.14 $1.24 Million - $1.72 Million
20,000 New
20,000 $1.29 Million
Q1 2019

May 10, 2019

BUY
$52.92 - $81.17 $0 - $0
0 New
0 $0
Q1 2019

May 10, 2019

BUY
$52.92 - $81.17 $0 - $0
0 New
0 $0
Q4 2018

Feb 12, 2019

BUY
$43.37 - $59.54 $0 - $0
0 New
0 $0
Q1 2018

May 14, 2018

SELL
$44.08 - $55.05 $0 - $0
0 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$50.3 - $64.39 $0 - $0
0 New
0 $0
Q3 2017

Nov 13, 2017

BUY
$45.56 - $59.57 $0 - $0
0
0 $0

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.83B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.